19 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
and Affordable Care Act, or the PPACA, authorized the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. Under
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
is included in the 2010 Patient Protection and Affordable Care Act, or the PPACA, authorized the FDA to approve similar versions of innovative biologics
8-K
EX-99.1
ZYME
Zymeworks Inc.
2 May 24
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:07pm
to enter multiple Phase 1 trials in the coming 24 months, our commitment to advancing innovative solutions remains evident, with more preclinical data
8-K
EX-99.1
ZYME
Zymeworks Inc.
28 Mar 24
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
4:16pm
with difficult-to-treat cancers and other serious diseases is evident in their innovative approach in developing next-generation product candidates. I am
8-K
EX-10.1
mrw5bx5
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
3cov5c92uu6c 3d9c
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
hitj7sgiivvhnzqi9lk
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
htfqv5zo dk516
21 Dec 22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
8:37am
DEF 14A
bfxf1xdmzc8y2f1gh2ci
25 Nov 22
Definitive proxy
6:16am
424B5
n3bsj4a obhon
9 Nov 22
Prospectus supplement for primary offering
4:29pm
10-Q
yzcp9rb799ttir
8 Nov 22
Quarterly report
4:09pm
424B5
doow57
21 Oct 22
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
amry9ow
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:26am
424B5
x9727 ghz8m
13 Oct 22
Prospectus supplement for primary offering
4:56pm
- Prev
- 1
- Next